RUH supports international stroke research study

Researchers at the Royal United Hospitals Bath NHS Foundation Trust are supporting an international study looking at whether a new drug could help reduce the risk of strokes reoccurring in patients.

The Librexia study is investigating whether the use of milvexian, an anticoagulant that thins the blood, helping to reduce the risks of blood clots from forming in the bloodstream, can reduce the risk of future ischaemic stroke in patients who have already suffered an ischaemic stroke or transient ischemic attack.

An ischaemic stroke happens when a blockage cuts off the blood supply to part of the brain, killing brain cells. This can result in speech and visual disturbance, and numbness or weakness in the face, arms and legs.

A transient ischaemic attack (TIA) is caused by a temporary disruption in the blood supply to part of the brain. This can cause sudden symptoms similar to a stroke.

Strokes affect around 100,000 people a year in the UK and are a leading cause of death and disability. While many people who have had a stroke go on to make a good recovery, others may experience another stroke.

Patients taking part in the study must be aged 40 or over and can sign up to be part of the study if they attend the RUH within 48hours of an ischaemic stroke or transient ischaemic attack.

Upon enrolment to the study, participants are randomly assigned to receive either milvexian or a placebo, in addition to standard medications suggested by their doctor.

Patients are then seen at the RUH every 13 weeks and for assessments, including blood tests and tests on liver and kidney function.

Kelly Spencer, Head of Research Operations at the RUH, said: “It’s fantastic that the RUH has been invited to be part of such an important study, which could lead to a really positive outcome for many of the people we care for.

“The RUH is well-respected for its commitment to research and studies like these reflect our ongoing work to support vital medical trials which can help us better care for our patients now and in the future.”